bluebird bio ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Trading Halts

UPDATE: bluebird bio's (BLUE) Zynteglo Gets FDA Approval - List Price In-Line Says AnalystAugust 17, 2022 4:22 PM bluebird bio (BLUE) call put ratio 6.8 calls to 1 put into confirms FDA approval of ZyntegloAugust 17, 2022 2:21 PM bluebird bio (BLUE) to Resume Trading at 2:30 p.m.August 17, 2022 2:10 PM bluebird bio (BLUE) Confirms FDA Approval of ZYNTEGLO Gene TherapyAugust 17, 2022 2:05 PM bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell TransfusionsAugust 17, 2022 2:03 PM bluebird bio (BLUE) to Charge $2.8M for Fda-Cleared Blood Disorder Therapy - BloombergAugust 17, 2022 1:54 PM FDA Approves bluebird bio's (BLUE) Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood TransfusionsAugust 17, 2022 1:40 PM bluebird bio (BLUE) Halted, News PendingAugust 17, 2022 12:41 PM